Ayala Pharmaceuticals Inc (ADXS)

[cab033]

Now that is a good question. They are sending the message that they plan on still being ADXS through roughly 2021-2022 which should take all BO talk off the table.

Enough cash now to get through 2018. 20M shares available to issue, even at a measly $5 is $100M. Assuming a cash burn rate or $50M per year, that gets them into 2021. Keep in mind this is assuming zero milestone payments and zero future non-dilutive cash deals, either of those could fund them another 6-12 months, right into 2022.

Going it alone is the message they are sending to the market with this.